Immunogen (IMGN) Misses Q3 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall St set for higher open tech gains offset bond-market jitters
- Oil prices rise 2% as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Alphabet shares up in premarket trade after Gemini 4 Argon launch
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
November 3, 2017 6:30 AM EDTCollaboration with Jazz Pharmaceuticals Accelerates Development of Early-Stage ADC Assets and Strengthens Financial Position
$100+ Million Follow-on Financing Provides Two-year Operating Runway
Presentations Accepted for ASH Annual Meeting Highlight Potential of Novel IGN Portfolio
IMGN632 Investigational New Drug Application Active
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS WIRE)--... More
